Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
Asian Markets Slide as Silver Volatility, Earnings Season, and Central Bank Meetings Rattle Investors 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Ancient Mars may have had a carbon cycle − a new study suggests the red planet may have once been warmer, wetter and more favorable for life 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
